New genetic and pharmacological treatments for cystic fibrosis

Current Pediatric Reviews

Volumn 5, Issue 1, 2009, Pages 8-27

  Conese, Massimo ^a,b   Romano, Mario ^c   Furnari, Maria Lucia ^d   Copreni, Elena ^b   De Fino, Ida ^b   Pardon, Francesca ^d   Galietta, Luis V J ^e  

^a UNIVERSITY OF FOGGIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d Cystic Fibrosis Centers of Geneva   (Italy)

^e G GASLINI INSTITUTE   (Italy)

Author keywords

Bacterial infection; CFTR (cystic fibrosis transmembrane conductance regulator); Correctors; ENaC (epithelial sodium channel); Gene therapy; Inflammation; Mucociliary clearance; Potentiators

Indexed keywords

ACETYLCYSTEINE; ADENOVIRUS VECTOR; AMIKACIN; AMILORIDE; AZITHROMYCIN; AZTREONAM; BIIL 284; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CYTOKINE; DORNASE ALFA; EPITHELIAL SODIUM CHANNEL; IBUPROFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOSOME; MANNITOL; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; NOVISPORIN G10; PLACEBO; POLYLYSINE; POLYPEPTIDE ANTIBIOTIC AGENT; SIMVASTATIN; SODIUM CHANNEL BLOCKING AGENT; STEROID; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZAFIRLUKAST;

ABSENCE OF SIDE EFFECTS; BURKHOLDERIA CEPACIA; BURKHOLDERIA CEPACIA INFECTION; CATARACT; CLINICAL TRIAL; CYSTIC FIBROSIS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EPITHELIUM CELL; ERADICATION THERAPY; GENE DELIVERY SYSTEM; GENE IDENTIFICATION; GENE ISOLATION; GENE MUTATION; GENE THERAPY; GENE TRANSFER; GLUCOSE INTOLERANCE; GROWTH RETARDATION; HUMAN; HYPERTENSION; IMMUNOMODULATION; INFLAMMATION; ION TRANSPORT; LIFESPAN; LUNG DISEASE; LUNG INFECTION; LUNG INJURY; LUNG TOXICITY; MICROBIAL COLONIZATION; MORBIDITY; MORTALITY; MUCOCILIARY CLEARANCE; MULTIDRUG RESISTANCE; NONHUMAN; OPPORTUNISTIC INFECTION; OXIDATION KINETICS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 65949116148     PISSN: 15733963     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339609787587555     Document Type: Review

References (248)

1. Cystic Fibrosis Foundation. Patient Registry 2004 Annual Report. Bethesda: Cystic Fibrosis Foundation 2005.
2. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003; 168: 918-51.
3. Mishra A, Greaves R, Massie J. The relevance of sweat testing for the diagnosis of cystic fibrosis in the genomic era. Clin Biochem Rev 2005; 26: 135-53.
4. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-65.
5. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245: 1066-73.
6. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989; 245: 1073-80.
7. Quinton PM. Missing Cl conductance in cystic fibrosis. Am J Physiol 1986; 251: C649-52.
8. Quinton PM. Physiological basis of cystic fibrosis: a historical perspective. Physiol Rev 1999; 79: S3-22.
9. Boucher RC. New concepts of the pathogenesis of cystic fibrosis lung disease. Eur Respir J 2004; 23: 146-58.
10. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005; 352: 1992-2001.
11. Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, Wilson JM. Expression of the cystic fibrosis gene in adult human lung. J Clin Invest 1994; 93: 737-9.
12. Kreda S, Mall M, Mengos A, et al. Characterization of wild-type and deltaF508 cystic fibrosis transmembrane regulator in human respiratory epithelia. Mol Biol Cell 2005; 16: 2154-67.
13. Boucher RC, Cotton CU, Gatzy JT, Knowles MR, Yankaskas JR. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol 1988; 405: 77-103.
14. Matsui H, Grubb BR, Tarran R, et al. Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airway disease. Cell 1998; 95: 1005-15.
15. Wine JJ, Joo NS. Submucosal glands and airway defense. Proc Am Thorac Soc 2004; 1: 47-53.
16. Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta 1999; 1461: 237-62.
17. Sheppard DN, Welsh MJ. Structure and function of the CFTR chloride channel. Physiol Rev 1999; 79: S23-45.
18. Welsh MJ, Smith AE. Molecolar mechanism of CFTR chloride channel dysfuction in cystic fibrosis. Cell 1993; 73: 1251-4.
19. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-4.
20. Lukacs GL, Mohamed A, Kartner N, Chang XB, Riordan JR, Grinstein S. Conformational maturation of CFTR but not its mutant counterpart (delta F508) occurs in the endoplasmic reticulum and requires ATP. EMBO J 1994; 13: 6076-86.
21. Du K, Sharma M, Lukacs GL. The DeltaF508 cystic fibrosis mutation impairs domain-domain interactions and arrests post-translational folding of CFTR. Nat Struct Mol Biol 2005; 12: 17-25.
22. Gregory RJ, Rich DP, Cheng SH, et al. Maturation and function of cystic fibrosis transmembrane conductance regulator variants bearing mutations in putative nucleotide-binding domains 1 and 2. Mol Cell Biol 1991; 11: 3886-93.
23. Illek B, Zhang L, Lewis NC, Moss RB, Dong JY, Fischer H. Defective function of the cystic fibrosis-causing missense mutation G551D is recovered by genistein. Am J Physiol 1999; 277: C833-9.
24. Sheppard DN, Rich DP, Ostedgaard LS, Gregory RJ, Smith AE, Welsh MJ. Mutations in CFTR associated with mild-disease-form Cl channels with altered pore properties. Nature 1993; 362: 160-4.
25. Rave-Harel N, Kerem E, Nissim-Rafinia M, et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet 1997; 60: 87-94.
26. Chiba-Falek O, Kerem E, Shoshani T, et al. The molecular basis of disease variability among cystic fibrosis patients carrying the 3849+10 kb C-->T mutation. Genomics 1998; 53: 276-83.
27. Chiba-Falek O, Parad RB, Kerem E, Kerem B. Variable levels of normal RNA in different fetal organs carrying a cystic fibrosis transmembrane conductance regulator splicing mutation. Am J Respir Crit Care Med 1999; 159: 1998-2002.
28. Haws CM, Nepomuceno IB, Krouse ME, et al. Delta F508-CFTR channels: kinetics, activation by forskolin, and potentiation by xanthines. Am J Physiol 1996; 270: C1544-55.
29. Ratjen F. Diagnosing and managing infection in CF. Paediatr Respir Rev 2006; 7(Suppl 1): S151-3.
30. Murray TS, Egan M, Kazmierczak BI. Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr Opin Pediatr 2007; 19: 83-8.
31. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006; 12: 428-32.
32. Canton R, Cobos N, de Gracia J, et al. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Clin Microbiol Infect 2005; 11: 690-703.
33. Rowe SM, Clancy JP. Advances in cystic fibrosis therapies. Curr Opin Pediatr 2006; 18: 604-13.
34. Koehler DR, Downey GP, Sweezey NB, Tanswell AK, Hu J. Lung inflammation as a therapeutic target in cystic fibrosis. Am J Respir Cell Mol Biol 2004; 31: 377-81.
35. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med 1996; 154: 1229-56.
36. Carrabino S, Carpani D, Livraghi A, et al. Dysregulated intereleukin-8 secretion and NF-κB activation in human cystic fibrosis nasal epithelial cells. J Cyst Fibros 2006; 5: 113-9.
37. Stecenko AA, King G, Torii K, et al. Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells. Inflammation 2001; 25: 145-55.
38. Perez A, Issler AC, Cotton CU, Kelley TJ, Verkman AS, Davis PB. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292: L383-95.
39. Painter RG, Valentine VG, Lanson NA Jr., et al. CFTR Expression in human neutrophils and the phagolysosomal chlorination defect in cystic fibrosis. Biochemistry 2006; 45: 10260-9.
40. Di A, Brown ME, Deriy LV, et al. CFTR regulates phagosome acidification in macrophages and alters bactericidal activity. Nat Cell Biol 2006; 8: 933-44.
41. Haggie PM, Verkman AS. Cystic fibrosis transmembrane conductance regulator-independent phagosomal acidification in macrophages. J Biol Chem 2007; 282: 31422-8.
42. Serhan CN, Brain SD, Buckley CD, et al. Resolution of inflammation: state of the art, definitions and terms. FASEB J 2007; 21: 325-32.
43. Karp CL, Flick LM, Park KW, et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 2004; 5: 388-92.
44. Vance RE, Hong S, Gronert K, Serhan CN, Mekalanos JJ. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 2004; 101: 2135-9.
45. Starner TD, McCray PB, Jr. Pathogenesis of early lung disease in cystic fibrosis: a window of opportunity to eradicate bacteria. Ann Intern Med 2005; 143: 816-22.
46. Wood DM, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2006; CD004197.
47. Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002; 1: 194-8.
48. Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 841-9.
49. Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20: 658-64.
50. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol 2007; 42: 307-13.
51. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003; 290: 1749-56.
52. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC. Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005; 172: 1008-12.
53. Retsch-Bogart GZ, Burns JL, Otto KL, et al. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2008; 43: 47-58.
54. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pages JM. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J Antimicrob Chemother 2007; 59: 1223-9.
55. Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61: 859-68.
56. Zhang L, Parente J, Harris SM, Woods DE, Hancock RE, Falla TJ. Antimicrobial peptide therapeutics for cystic fibrosis. Antimicrob Agents Chemother 2005; 49: 2921-7.
57. Song Z, Wu H, Mygind P, et al. Effects of intratracheal administration of novispirin G10 on a rat model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob Agents Chemother 2005; 49: 3868-74.
58. Musk DJ, Jr., Hergenrother PJ. Chemical countermeasures for the control of bacterial biofilms: effective compounds and promising targets. Curr Med Chem 2006; 13: 2163-77.
59. Yoon SS, Coakley R, Lau GW, et al. Anaerobic killing of mucoid Pseudomonas aeruginosa by acidified nitrite derivatives under cystic fibrosis airway conditions. J Clin Invest 2006; 116: 436-46.
60. Middleton PG, Kidd TJ, Williams B. Combination aerosol therapy to treat Burkholderia cepacia complex. Eur Respir J 2005; 26: 305-8.
61. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000; CD000407.
62. Balfour-Lynn I, Walters S, Dezateux C. Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev 2000; CD001915.
63. Lucidi V, Tozzi AE, Bella S, Turchetta A. A pilot trial on safety and efficacy of erythrocyte-mediated steroid treatment in CF patients. BMC Pediatr 2006; 6: 17.
64. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995; 332: 848-54.
65. Konstan MW, Schluchter MD, Storfer-Isser, Davis PB. Use of ibuprofen for the treatment of airway in flammation in CF: an update. Ped Pulmunol 2002; Suppl 24: 164-5.
66. Schluchter MD, Konstan MW, Xue L, Davis PB. Relationship between high-dose ibuprofen use and rate of decline in FEV1 among young patients with mild lung disease in the CFF Registry. Ped Pulmunol 2004; Suppl 27: 322.
67. Lands LC, Milner R, Cantin AM, Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007; 151: 249-54.
68. Rodriguez LA, Patrignani P. The ever growing story of cyclooxygenase inhibition. Lancet 2006; 368: 1745-7.
69. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169: 719-25.
70. Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001; 139: 813-20.
71. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 1084-9.
72. McKenzie SG, Chowdhury S, Strandvik B, Hodson ME. Dornase alfa is well tolerated: data from the epidemiologic registry of cystic fibrosis. Pediatr Pulmonol 2007; 42: 928-37.
73. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-95.
74. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 1871-5.
75. Okuno T, Yokomizo T, Hori T, Miyano M, Shimizu T. Leukotriene B4 receptor and the function of its helix 8. J Biol Chem 2005; 280: 32049-52.
76. Carpagnano GE, Barnes PJ, Geddes DM, Hodson ME, Kharitonov SA. Increased leukotriene B4 and interleukin-6 in exhaled breath condensate in cystic fibrosis. Am J Respir Crit Care Med 2003; 167: 1109-12.
77. Konstan MW, Doring G, Lands LC, et al. Results of a phase II clinical trial of BIIL 284 BS (a LTB4 receptor antagonist) for the treatment of CF lung disease. Ped Pulmunol 2005; (Suppl 28): 125-7.
78. Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol 2005; 174: 589-94.
79. Evans JF. The cysteinyl leukotriene receptors. Prostaglandins Leukot Essent Fatty Acids 2003; 69: 117-22.
80. Capra V, Ambrosio M, Riccioni G, Rovati GE. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006; 13: 3213-26.
81. Morice AH, Kastelik JA, Aziz I. Montelukast sodium in cystic fibrosis. Thorax 2001; 56: 244-5.
82. Schmitt-Grohe S, Eickmeier O, Schubert R, Bez C, Zielen S. Antiinflammatory effects of montelukast in mild cystic fibrosis. Ann Allergy Asthma Immunol 2002; 89: 599-605.
83. Stelmach I, Korzeniewska A, Stelmach W, Majak P, Grzelewski T, Jerzynska J. Effects of montelukast treatment on clinical and inflammatory variables in patients with cystic fibrosis. Ann Allergy Asthma Immunol 2005; 95: 372-80.
84. Conway SP, Etherington C, Peckham DG, Whitehead A. A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. J Cyst Fibros 2003; 2: 25-8.
85. Xu Y, Liu C, Clark JC, Whitsett JA. Functional genomic responses to cystic fibrosis transmembrane conductance regulator (CFTR) and CFTR(delta508) in the lung. J Biol Chem 2006; 281: 11279-91.
86. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628-33.
87. Zheng S, De BP, Choudhary S, et al. Impaired innate host defense causes susceptibility to respiratory virus infections in cystic fibrosis. Immunity 2003; 18: 619-30.
88. Robroeks CM, Rosias PP, van Vliet D, et al. Biomarkers in exhaled breath condensate indicate presence and severity of cystic fibrosis in children. Pediatr Allergy Immunol 2008; 19: 652-9.
89. Kraynack NC, Corey DA, Elmer HL, Kelley TJ. Mechanisms of NOS2 regulation by Rho GTPase signaling in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2002; 283: L604-11.
90. Yin R, Zhu J, Shao H, et al. Inhibition of chemokine receptor CCR2 and CCR5 expression contributes to simvastatin-induced attenuation of cardiac allograft vasculopathy. J Heart Lung Transplant 2007; 26: 485-93.
91. Lee JY, Kim JS, Kim JM, Kim N, Jung HC, Song IS. Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis. Int Immunopharmacol 2007; 7: 241-8.
92. Bruegel M, Teupser D, Haffner I, Mueller M, Thiery J. Statins reduce macrophage inflammatory protein-1alpha expression in human activated monocytes. Clin Exp Pharmacol Physiol 2006; 33: 1144-9.
93. Fischetti F, Carretta R, Borotto G, et al. Fluvastatin treatment inhibits leucocyte adhesion and extravasation in models of complement-mediated acute inflammation. Clin Exp Immunol 2004; 135: 186-93.
94. Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F. Oral L-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 2005; 25: 62-8.
95. Huang TH, Razmovski-Naumovski V, Kota BP, Lin DS, Roufogalis BD. The pathophysiological function of peroxisome proliferator-activated receptor-gamma in lung-related diseases. Respir Res 2005; 6: 102.
96. Ollero M, Junaidi O, Zaman MM, et al. Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice. J Cell Physiol 2004; 200: 235-44.
97. Wang AC, Dai X, Luu B, Conrad DJ. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol 2001; 24: 688-93.
98. Asada K, Sasaki S, Suda T, Chida K, Nakamura H. Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 2004; 169: 195-200.
99. Belvisi MG, Hele DJ, Birrell MA. Peroxisome proliferator-activated receptor gamma agonists as therapy for chronic airway inflammation. Eur J Pharmacol 2006; 533: 101-9.
100. Chmiel JF, Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007; 28: 331-46.
101. Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Lester Kirchner H, Berger M. Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 2002; 165: 1176-81.
102. Chmiel JF, Konstan MW, Knesebeck JE, et al. IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 1999; 160: 2040-7.
103. Souza DG, Fagundes CT, Amaral FA, et al. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007; 179: 8533-43.
104. Kelley TJ, Elmer HL. In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. J Clin Invest 2000; 106: 403-10.
105. Moss RB, Mayer-Hamblett N, Wagener J, et al. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 2005; 39: 209-18.
106. McElvaney NG, Hubbard RC, Birrer P, et al. Aerosol alpha 1-antitrypsin treatment for cystic fibrosis. Lancet 1991; 337: 392-4.
107. Griese M, Latzin P, Kappler M, et al. alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29: 240-50.
108. Grimbert D, Vecellio L, Delepine P, et al. Characteristics of EPI-hNE4 aerosol: a new elastase inhibitor for treatment of cystic fibrosis. J Aerosol Med 2003; 16: 121-9.
109. Delacourt C, Herigault S, Delclaux C, et al. Protection against acute lung injury by intravenous or intratracheal pretreatment with EPI-HNE-4, a new potent neutrophil elastase inhibitor. Am J Respir Cell Mol Biol 2002; 26: 290-7.
110. Ianaro A, Ialenti A, Maffia P, et al. Anti-inflammatory activity of macrolide antibiotics. J Pharmacol Exp Ther 2000; 292: 156-63.
111. Pukhalsky AL, Shmarina GV, Kapranov NI, Kokarovtseva SN, Pukhalskaya D, Kashirskaja NJ. Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease. Mediators Inflamm 2004; 13: 111-7.
112. Romano M. Lipid mediators: lipoxin and aspirin-triggered 15-epilipoxins. Inflamm Allergy Drug Targets 2006; 5: 81-90.
113. Ariel A, Serhan CN. Resolvins and protectins in the termination program of acute inflammation. Trends Immunol 2007; 28: 176-83.
114. Freedman SD, Katz MH, Parker EM, Laposata M, Urman MY, Alvarez JG. A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice. Proc Natl Acad Sci USA 1999; 96: 13995-4000.
115. Van Biervliet S, Van Biervliet JP, Robberecht E, Christophe A. Docosahexaenoic acid trials in cystic fibrosis: a review of the rationale behind the clinical trials. J Cyst Fibros 2005; 4: 27-34.
116. Jumpsen JA, Brown NE, Thomson AB, et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. J Cyst Fibros 2006; 5: 77-84.
117. Beharry S, Ackerley C, Corey M, et al. Long-term docosahexaenoic acid therapy in a congenic murine model of cystic fibrosis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G839-48.
118. Alton E. Progress and Prospects: Gene Therapy Clinical Trials (Part 1). Gene Ther 2007; 14: 1439-47.
119. Zeitlin PL. Cystic fibrosis gene therapy trials and tribulations. Mol Ther 2000; 1: 5-6.
120. Davies JC, Geddes DM, Alton EWFW. Gene therapy for cystic fibrosis. J Gene Med 2001; 3: 409-17.
121. Lee TW, Matthews DA, Blair GE. Novel molecular approaches to cystic fibrosis gene therapy. Biochem J 2005; 387: 1-15.
122. Harvey BG, Leopold PL, Hackett NR, et al. Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administrations of a recombinant adenovirus. J Clin Invest 1999; 104: 1245-55.
123. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000; 7: 1156-65.
124. Ziady AG, Davis PB, Konstan MW. Non-viral gene transfer therapy for cystic fibrosis. Expert Opin Biol Ther 2003; 3: 449-58.
125. Jiang C, O'Connor S, Fang SL, et al. Efficiency of cationic lipid-mediated transfection of polarized and differentiated airway epithelial cells In vitro and in vivo. Hum Gene Ther 1998; 9: 1531-42.
126. Ziady AG, Davis PB. Current prospects for gene therapy of cystic fibrosis. Curr Opin Pharmacol 2006; 6: 515-21.
127. Lee ER, Marshall J, Siegel CS, et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996; 7: 1701-17.
128. Zabner J, Cheng SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997; 100: 1529-37.
129. Alton EWFW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet 1999; 353: 947-54.
130. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008; 26: 549-51.
131. Gill DR, Smyth SE, Goddard CA, et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin elongation factor 1alpha promoter. Gene Ther 2001; 8: 1539-46.
132. McLachlan G, Baker A, Tennant P, et al. Optimizing aerosol gene delivery and expression in the ovine lung. Mol Ther 2007; 15: 348-54.
133. Alton EWFW. Use of nonviral vectors for cystic fibrosis gene therapy. Proc Am Thorac Soc 2004; 1: 296-301.
134. Alton EW, Davies JC, Geddes DM. Biomarkers for cystic fibrosis: are we progressing? Am J Respir Crit Care Med 2007; 175: 750-1.
135. Macgregor G, Gray RD, Hilliard TN, et al. Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros 2008; 7:352-8.
136. Ziady AG, Gedeon CR, Miller T, et al. Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo. Mol Ther 2003; 8: 936-47.
137. Ziady AG, Gedeon CR, Muhammad O, et al. Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung. Mol Ther 2003; 8: 948-56.
138. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004; 15: 1255-69.
139. Densmore CL. Advances in noninvasive pulmonary gene therapy. Curr Drug Deliv 2006; 3: 55-63.
140. Densmore CL, Orson FM, Xu B, et al. Aerosol delivery of robust polyethylenimine-DNA complexes for gene therapy and genetic immunization. Mol Ther 2000; 1: 180-8.
141. Gautam A, Densmore CL, Xu B, Waldrep JC. Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol Ther 2000; 2: 63-70.
142. Koshkina NV, Agoulnik IY, Melton SL, Densmore CL, Knight V. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethylenimine complexes: optimization and pulmonary delivery and retention. Mol Ther 2003; 8: 249-54.
143. Gautam A, Densmore CL, Waldrep JC. Pulmonary cytokine response associated with PEI-DNA aerosol gene therapy. Gene Ther 2001; 8: 254-7.
144. Davies LA, McLachlan G, Sumner-Jones SG, et al. Enhanced lung gene expression after aerosol delivery of concentrated pDNA/PEI complexes. Mol Ther 2008; 16:1283-90.
145. Genta Salus LLC. US7060498; 2006.
146. Expression Genetics, Inc. US6696038; 2004.
147. University of Utah Research Foundation. US7183263; 2007.
148. Griesenbach U, Geddes DM, Alton EW. Gene therapy for cystic fibrosis: an example for lung gene therapy. Gene Ther 2004; 11(Suppl 1): S43-50.
149. Koehler DR, Martin B, Corey M, et al. Readministration of helper-dependent adenovirus to mouse lung. Gene Ther 2006; 13: 773-80.
150. Toietta G, Koehler DR, Finegold MJ, Lee B, Hu J, Beaudet al. Reduced inflammation and improved airway expression using helper-dependent adenoviral vectors with a K18 promoter. Mol Ther 2003; 7: 649-58.
151. Flotte TR. Adeno-associated virus-based gene therapy for inherited disorders. Pediatr Res 2005; 58: 1143-7.
152. Flotte TR, Zeitlin PL, Reynolds TC, et al. Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study. Hum Gene Ther 2003; 14: 1079-88.
153. Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125: 509-21.
154. Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007; 18: 726-32.
155. Fischer AC, Beck SE, Smith CI, et al. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther 2003; 8: 918-26.
156. Limberis MP, Wilson JM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci USA 2006; 103: 12993-8.
157. Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther 2007; 15: 756-63.
158. Sirninger J, Muller C, Braag S, et al. Functional characterization of a recombinant adeno-associated virus 5-pseudotyped cystic fibrosis transmembrane conductance regulator vector. Hum Gene Ther 2004; 15: 832-41.
159. Mueller C, Flotte TR. Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Ther 2008; 15: 858-63.
160. Zhang L, Bukreyev A, Thompson CI, et al. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 2005; 79: 1113-24.
161. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 2002; 76: 5654-66.
162. Yonemitsu Y, Kitson C, Ferrari S, et al. Efficient gene transfer to airway epithelium using recombinant Sendai virus. Nat Biotechnol 2000; 18: 970-3.
163. Ferrari S, Griesenbach U, Iida A, et al. Sendai virus-mediated CFTR gene transfer to the airway epithelium. Gene Ther 2007; 14: 1371-9.
164. Ban H, Inoue M, Griesenbach U, et al. Expression and maturation of Sendai virus vector-derived CFTR protein: functional and biochemical evidence using a GFP-CFTR fusion protein. Gene Ther 2007; 14: 1688-94.
165. Ferrari S, Griesenbach U, Shiraki-Iida T, et al. A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo. Gene Ther 2004; 11: 1659-64.
166. Griesenbach U, Boyton RJ, Somerton L, et al. Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration. Gene Ther 2006; 13: 449-56.
167. Keriel A, Rene C, Galer C, Zabner J, Kremer EJ. Canine adenovirus vectors for lung-directed gene transfer: efficacy, immune response, and duration of transgene expression using helper-dependent vectors. J Virol 2006; 80: 1487-96.
168. Wilson JM. Adeno-associated virus and lentivirus pseudotyped for lung-directed gene therapy. Proc Am Thorac Soc 2004; 1: 309-14.
169. Copreni E, Penzo M, Carrabino S, Conese M. Lentiviral-mediated gene transfer to the respiratory epithelium: a promising approach to gene therapy of Cystic Fibrosis. Gene Ther 2004; 11: S67-75.
170. Limberis M, Anson DS, Fuller M, Parsons DW. Recovery of airway cystic fibrosis transmembrane conductance regulator function in mice with cystic fibrosis after single-dose lentivirus-mediated gene transfer. Hum Gene Ther 2002; 13: 1961-70.
171. Sinn PL, Burnight ER, Hickey MA, Blissard GW, McCray PB, Jr. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. J Virol 2005; 79: 12818-27.
172. Sinn PL, Penisten AK, Burnight ER, et al. Gene transfer to respiratory epithelia with lentivirus pseudotyped with Jaagsiekte sheep retrovirus envelope glycoprotein. Hum Gene Ther 2005; 16: 479-88.
173. McKay T, Patel M, Pickles RJ, Johnson LG, Olsen JC. Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther 2006; 13: 715-24.
174. Flotte TR, Ng P, Dylla DE, et al. Viral vector-mediated and cell-based therapies for treatment of cystic fibrosis. Mol Ther 2007; 15: 229-41.
175. Tarantal AF, McDonald RJ, Jimenez DF, et al. Intrapulmonary and intramyocardial gene transfer in rhesus monkeys (Macaca mulatta): safety and efficiency of HIV-1-derived lentiviral vectors for fetal gene delivery. Mol Ther 2005; 12: 87-98.
176. Skarsgard ED, Huang L, Reebye SC, Yeung AY, Jia WW. Lentiviral vector-mediated, in vivo gene transfer to the tracheobronchial tree in fetal rabbits. J Pediatr Surg 2005; 40: 1817-21.
177. Buckley SM, Howe SJ, Sheard V, et al. Lentiviral transduction of the murine lung provides efficient pseudotype and developmental stage-dependent cell-specific transgene expression. Gene Ther 2008; 15:1167-75.
178. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2: 467-9.
179. Bedwell DM, Kaenjak A, Benos DJ, et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3: 1280-4.
180. Clancy JP, Bebok Z, Ruiz F, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001; 163: 1683-92.
181. Wilschanski M, Yahav Y, Yaacov Y, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003; 349: 1433-41.
182. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
183. Rubenstein RC, Egan ME, Zeitlin PL. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR. J Clin Invest 1997; 100: 2457-65.
184. Rubenstein RC, Zeitlin PL. A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med 1998; 157: 484-90.
185. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000; 278: C259-67.
186. Zeitlin PL, Diener-West M, Rubenstein RC, Boyle MP, Lee CK, Brass-Ernst L. Evidence of CFTR function in cystic fibrosis after systemic administration of 4-phenylbutyrate. Mol Ther 2002; 6: 119-126.
187. Egan ME, Glockner-Pagel J, Ambrose C, et al. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 2002; 8: 485-92.
188. Egan ME, Pearson M, Weiner SA, et al. Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science 2004; 304: 600-2.
189. Song Y, Sonawane ND, Salinas D, et al. Evidence against the rescue of defective ΔF508-CFTR cellular processing by curcumin in cell culture and mouse models. J Biol Chem 2004; 279: 40629-33.
190. Loo TW, Bartlett MC, Clarke DM. Thapsigargin or curcumin does not promote maturation of processing mutants of the ABC transporters, CFTR, and P-glycoprotein. Biochem Biophys Res Commun 2004; 325: 580-5.
191. Dragomir A, Bjorstad J, Hjelte L, Roomans GM. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells. Biochem Biophys Res Commun 2004; 322: 447-51.
192. Grubb BR, Gabriel SE, Mengos A, et al. SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol 2006; 34: 355-63.
193. Becq F, Mettey Y, Gray MA, et al. Development of substituted Benzo[c]quinolizinium compounds as novel activators of the cystic fibrosis chloride channel. J Biol Chem 1999; 274: 27415-25.
194. Derand R, Bulteau-Pignoux L, Mettey Y, et al. Activation of G551D CFTR channel with MPB-91: regulation by ATPase activity and phosphorylation. Am J Physiol Cell Physiol 2001; 281: C1657-66.
195. Marivingt-Mounir C, Norez C, Derand R, et al. Synthesis, SAR, crystal structure, and biological evaluation of benzoquinoliziniums as activators of wild-type and mutant cystic fibrosis transmembrane conductance regulator channels. J Med Chem 2004; 47: 962-72.
196. Dormer RL, Derand R, McNeilly CM, et al. Correction of delF508-CFTR activity with benzo(c)quinolizinium compounds through facilitation of its processing in cystic fibrosis airway cells. J Cell Sci 2001; 114: 4073-81.
197. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005; 115: 2564-71.
198. Van Goor F, Straley KS, Cao D, et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006; 290: L1117-30.
199. Loo TW, Bartlett MC, Clarke DM. Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm 2005; 2: 407-13.
200. Zaman K, Carraro S, Doherty J, et al. S-nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol Pharmacol 2006; 70: 1435-42.
201. Servetnyk Z, Krjukova J, Gaston B, et al. Activation of chloride transport in CF airway epithelial cell lines and primary CF nasal epithelial cells by S-nitrosoglutathione. Respir Res 2006; 7: 124.
202. Illek B, Fischer H, Santos GF, Widdicombe JH, Machen TE, Reenstra WW. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am J Physiol 1995; 268: C886-93.
203. Hwang TC, Wang F, Yang IC, Reenstra WW. Genistein potentiates wild-type and delta F508-CFTR channel activity. Am J Physiol 1997; 273: C988-98.
204. Illek B, Fischer H. Flavonoids stimulate Cl conductance of human airway epithelium in vitro and in vivo. Am J Physiol 1998; 275: L902-10.
205. Zegarra-Moran O, Romio L, Folli C, et al. Correction of G551D-CFTR transport defect in epithelial monolayers by genistein but not by CPX or MPB-07. Br J Pharmacol 2002; 137: 504-12.
206. Galietta LJ, Springsteel MF, Eda M et al. Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001; 276: 19723-8.
207. Yang H, Shelat AA, Guy RK, et al. Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003; 278: 35079-85.
208. Pedemonte N, Sonawane ND, Taddei A, et al. Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005; 67: 1797-807.
209. Bulteau L, Derand R, Mettey Y, et al. Properties of CFTR activated by the xanthine derivative X-33 in human airway Calu-3 cells. Am J Physiol Cell Physiol 2000; 279: C1925-37.
210. Gribkoff VK, Champigny G, Barbry P, Dworetzky SI, Meanwell NA, Lazdunski M. The substituted benzimidazolone NS004 is an opener of the cystic fibrosis chloride channel. J Biol Chem 1994; 269: 10983-6.
211. Al-Nakkash L, Hu S, Li M, Hwang TC. A common mechanism for cystic fibrosis transmembrane conductance regulator protein activation by genistein and benzimidazolone analogs. J Pharmacol Exp Ther 2001; 296: 464-72.
212. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005; 68: 1736-46.
213. Ai T, Bompadre SG, Wang X, Hu S, Li M, Hwang TC. Capsaicin potentiates wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride-channel currents. Mol Pharmacol 2004; 65: 1415-26.
214. Bachmann A, Russ U, Waldegger S, Quast U. Potent stimulation and inhibition of the CFTR Cl(-) current by phloxine B. Br J Pharmacol 2000; 131: 433-40.
215. Cai Z, Sheppard DN. Phloxine B interacts with the cystic fibrosis transmembrane conductance regulator at multiple sites to modulate channel activity. J Biol Chem 2002; 277: 19546-53.
216. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-50.
217. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. Curr Opin Pulm Med 2006; 12: 445-52.
218. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007; 42: 471-6.
219. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006; 354: 229-40.
220. Kohler D, App E, Schmitz-Schumann M, Wurtemberger G, Matthys H. Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl 1986; 146: 319-26.
221. App EM, King M, Helfesrieder R, Kohler D, Matthys H. Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 1990; 141: 605-12.
222. Knowles MR, Church NL, Waltner WE, et al. A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 1990; 322: 1189-94.
223. Graham A, Hasani A, Alton EW, et al. No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 1993; 6: 1243-8.
224. Bowler IM, Kelman B, Worthington D, et al. Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 1995; 73: 427-30.
225. Pons G, Marchand MC, d'Athis P, et al. French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. The Amiloride-AFLM Collaborative Study Group. Pediatr Pulmonol 2000; 30: 25-31.
226. Hirsh AJ. Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 2002; 54: 1445-62.
227. Hirsh AJ, Sabater JR, Zamurs A, et al. Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2004; 311: 929-38.
228. Hirsh AJ, Zhang J, Zamurs A, et al. Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N′-4- [4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 2008; 325: 77-88.
229. Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999; 14: 678-85.
230. Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008; 133: 1388-96.
231. Mall M, Wissner A, Gonska T, et al. Inhibition of amiloride-sensitive epithelial Na(+) absorption by extracellular nucleotides in human normal and cystic fibrosis airways. Am J Respir Cell Mol Biol 2000; 23: 755-61.
232. Knowles MR, Clarke LL, Boucher RC. Activation by extracellular nucleotides of chloride secretion in the airway epithelia of patients with cystic fibrosis. N Engl J Med 1991; 325: 533-8.
233. Deterding R, Retsch-Bogart G, Milgram L, et al. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 2005; 39: 339-48.
234. Deterding RR, Lavange LM, Engels JM, et al. Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med 2007; 176: 362-9.
235. Zeitlin PL, Boyle MP, Guggino WB, Molina L. A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest 2004; 125: 143-9.
236. Grasemann H, Stehling F, Brunar H, et al. Inhalation of Moli1901 in patients with cystic fibrosis. Chest 2007; 131: 1461-6.
237. Ratjen F. New pulmonary therapies for cystic fibrosis. Curr Opin Pulm Med 2007; 13: 541-6.
238. Henke MO, John G, Germann M, Lindemann H, Rubin BK. MUC5AC and MUC5B mucins increase in cystic fibrosis airway secretions during pulmonary exacerbation. Am J Respir Crit Care Med 2007; 175: 816-21.
239. Henke MO, Renner A, Huber RM, Seeds MC, Rubin BK. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions. Am J Respir Cell Mol Biol 2004; 31: 86-91.
240. Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr Respir Rev 2007; 8: 24-9.
241. Vasconcellos CA, Allen PG, Wohl ME, Drazen JM, Janmey PA, Stossel TP. Reduction in viscosity of cystic fibrosis sputum in vitro by gelsolin. Science 1994; 263: 969-71.
242. Rubin BK, Kater AP, Goldstein AL. Thymosin beta4 sequesters actin in cystic fibrosis sputum and decreases sputum cohesivity in vitro. Chest 2006; 130: 1433-40.
243. Kater A, Henke MO, Rubin BK. The role of DNA and actin polymers on the polymer structure and rheology of cystic fibrosis sputum and depolymerization by gelsolin or thymosin beta 4. Ann NY Acad Sci 2007; 1112: 140-53.
244. Grubb BR, Boucher RC. Pathophysiology of gene-targeted mouse models for cystic fibrosis. Physiol Rev 1999; 79: S193-214.
245. Sun X, Yan Z, Yi Y, et al. Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets. J Clin Invest 2008; 118: 1578-83.
246. Rogers CS, Hao Y, Rokhlina T, et al. Production of CFTR-null and CFTR-DeltaF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer. J Clin Invest 2008; 118: 1571-7.
247. Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther 2005; 16: 921-8.
248. Duszyk M, MacVinish L, Cuthbert AW. Phenanthrolines - a new class of CFTR chloride channel openers. Br J Pharmacol 2001; 134: 853-64.